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(D50) were fitting parameters and studies were weighted using inverse 
variance (see Eq. 1).  
PRFS=1/(1+exp(4·γ50·(1-D/D50))) [Eq.1] 
Results: A total of ca 4000 publications were reviewed of which 15 
met the acceptance criteria, providing a total of 28 dose level 
outcome data at 1-4 time points. A total of 6/28 were using IG-IMRT, 
7/28 IMRT, 15/28 3DCRT and 6/28 were randomized trials. IG, IMRT 
and radiation dose were associated with improved PRFS at 5 years 
(Table 1), while randomized trials (yes/no), the frequency of use or 
duration of ADT were not.Only the radiation dose remained significant 
in a multivariate analysis, indicating that a pooled analysis of all 
studies was reasonable. The gradient of the dose response curve (γ50) 
was ca 1.5% at 3-7 years, and the dose required to obtain 50% PRFS 
(D50) was significantly different at 3 vs. 5 and 7 years (p<0.001) (Fig. 
1.). A reduction of 6% in PRFS per year was estimated for year 3-5 
post RT. Increased treatment margin tended to improve PRFS 
independent of IGRT use. No publication bias was evident.  
 
 
 
Conclusions: High-dose IG-IMRT was associated with superior PRFS vs. 
low-dose RT for high-risk PCa. PRFS at 3 years can potentially be used 
to predict outcome at 4-7 years. The possibility of a minor effect on 
PRFS by reducing the treatment margin could be discerned. By 
extrapolation of our model, RT to ca 85-95 Gy in equivalent dose in 2-
Gy fractions is predicted to improve PRFS for high-risk PCa, after 
which the local control plateaus and the benefit diminishes.  
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Purpose/Objective: The dose-response relationship for prostate 
radiotherapy has been demonstrated in several clinical trials with an 
advantage for high dose treatments. Established prognostic factors; 
including tumour stage, Gleason score, and PSA explain only a 
moderate proportion of the variation in outcome following prostate 
radiotherapy. There are no reliable predictors to determine which 
patients are likely to benefit from the extra dose. Prostate cancer 
exhibits regions of hypoxia with oxygen partial pressures that are 
likely to have radiobiological significance. The concept of the oxygen 
enhancement ratio is well established and it is possible that hypoxia 
biomarkers may predict which patients require dose escalation. We 
aimed to study the predictive value of intrinsic biomarkers of tumour 
hypoxia (GLUT1, HIF1α and osteopontin (OPN)) in patients treated 
with radiotherapy for localised prostate cancer. 
Materials and Methods: Paraffin embedded prostate biopsies were 
collected from patients enrolled into a trial of external beam 
radiotherapy (EBRT) versus combined EBRT followed by a high dose 
rate (HDR) brachytherapy boost.  
Immunohistochemical staining was performed for GLUT1, HIF1αand 
OPN using monoclonal antibodies. Tumours were assessed for 
biomarker expression by two independent investigators, blinded to 
patient outcome and scored as negative or positive depending upon 
the proportion of cells staining for the marker in question. 
Biochemical relapse free interval for all patients was determined 
using the Kaplan-Meier method. 
Results: 191 samples were included in the analysis. Hif1α, Glut1 and 
OPN expression were all significantly associated with a shorter 
biochemical relapse free interval (see figure and table). High dose 
radiotherapy (EBRT plus HDR boost) was advantageous over 
conventional dose radiotherapy (EBRT alone) for patients that 
exhibited OPN expression (p=0.017) but not for patients with negative 
OPN staining (p=0.349). Conversely, for GLUT1, high dose 
radiotherapy was only advantageous over conventional dose 
radiotherapy for patients that lacked GLUT1 expression (p=0.006).  
 
 
  
Conclusions: Overall, expression of OPN, HIF1α or GLUT1 confers a 
poorer prognosis for patients receiving prostate radiotherapy 
compared to those that do not express these hypoxia biomarkers. 
Furthermore, these data generate the following hypothesis: OPN 
becomes positive in the presence of mild/moderate hypoxia, GLUT1 
only becomes positive under conditions of severe hypoxia. Therefore, 
If both OPN and GLUT1 are negative (i.e. minimal hypoxia), there is 
no benefit from dose escalation. If OPN is positive and GLUT1 is 
negative (moderate hypoxia), there is a benefit for dose escalation. 
However, If GLUT1 is positive (severe hypoxia), there is no benefit 
from dose escalation because patients will do badly despite very high 
doses of radiotherapy. Further evaluation using an independent data 
set is ongoing.  
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Purpose/Objective: Daily location of the target volume has become a 
usual clinical practice after introduction of portal imaging devices. 
The actual information on the day of treatment is used to relocate the 
patient to maximize target coverage. However, relocation is not 
capable to account for large deformations of structures of interest, 
and the therapeutic ratio remains lower then desired. We propose a 
method of generating triple-arc IMAT plans to treat prostate cancer 
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patients. The plans allow geometrical ad-hoc adaptation to large 
interfractional deformations of patient geometry.  
Materials and Methods: Patients with intermediate or high-risk 
prostate cancer are normally treated using VMAT technique with 
Simultaneously Integrated Boost at our department. The CTV is 
defined as the prostate and the base of seminal vesicles. The Boost 
(PTV) is obtained by expanding the CTV by 5 (10) mm. Prescription 
doses to PTV and Boost are respectively 60.1 and 74 Gy given in 33 
fractions. 
Our method of IMAT for prostate cancer uses three arcs. We analyze 
the geometry of the structures of interest (PTV and rectum), and 
generate segments to deliver three fluence steps: conformal (Step 0, 
first arc), sparing the rectum (Step 1, second arc), and narrow 
segments compensating for the underdosage in the PTV due to rectum 
sparing (Step 2, third arc). The width of Step 2 segments is calculated 
for every MLC leaf pair based on the PTV and rectum geometry in the 
corresponding CT layer to have best dose homogeneity. The segments 
are then fed into the DMPO engine of Pinnacle for weight optimization 
and fine-tuning of the form. We call this method '2-Step IMAT'. 2-Step 
IMAT and reference VMAT plans show highly equivalent target 
coverage, rectum sparing, and dosimetric quality, with 2-Step IMAT 
taking on average 230 sec to deliver vs 100 sec for VMAT. 
We adapt 2-Step IMAT plans to changed geometry preserving the 
number of Monitor Units (MU) calculated for each segment at initial 
geometry. The leaves of Step 0 segments follow the edges of the PTV 
in Beam Eye View to keep PTV conformally irradiated. The leaves of 
Step 1 segments follow the edges of the rectum to keep it spared. For 
Step 2 segments, the opening of each leaf pair is adapted to the 
geometry change in the corresponding CT layer to have best dose 
homogeneity under the condition of MU preservation.  
Results: Four adaptation cases have been considered. The ones having 
best and worst improvement of target coverage between relocated 
and adapted plan are shown in Fig.1 a,b and Tab. 1. The target 
coverage is measured by SD index which sums up violations of dose 
requirements for Boost and PTV-Boost:  
 
To characterize rectum sparing we measure absolute rectum volumes 
cut out by 95%-, 80%-, and 50%-isodose.  
 
 
Fig.1. DVHs for the adaptation cases with the best (a) and the worst 
(b) target coverage: dotted – relocation, thin – new optimization, 
thick – adaptation. 
 Tab.1. Evaluation for Fig.1. 
 
Conclusions: The 2-Step IMAT method delivers prostate plans 
equivalent to the reference VMAT plans. On the expense of 2-3 longer 
delivery time 2-Step IMAT plans offer the possibility to adapt to large 
interfractional changes of patient geometry. 
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Purpose/Objective: Concurrent chemoradiotherapy has been a 
standard treatment for good performance status patients with 
unresectable stage III non–small cell lung cancer (NSCLC). However, 
the toxicities were not neglected. To evaluate pemetrexed in 
combination with cisplatin in these patients, a randomized phase III 
study of concurrent cisplatin with pemtrexed or vinorelbine and late 
course accelerated hyperfractionated radiotherapy (LCAHRT) was 
performed. 
Materials and Methods: Total of 86 patients were randomly assigned 
to two concurrent regimens beforeMarch 2012. Arm1 included 
cisplatin at 25 mg/m2 on days 1-3, 22-24 and vinorelbine at 25 mg/m2 
on days 1,8 and 22,29 with concurrent late course accelerated 
hyperfractionated radiotherapy. Arm 2 used cisplatin at 25 mg/m2 on 
days 1-3, 22-24 and pemtrexed at 500 mg/m2 on days 1 and 22 with 
the same radiotherapy protocol. The primary endpoint was overall 
survival (OS), and secondary endpoints included toxicities. Kaplan–
Meier analyses were used to assess survival, and toxic effects were 
examined using the Pearson Chi-Square test. All statistical tests were 
two-sided. 
Results: 84 patients were analyzed for 2 patients in arm 1 were not 
finished treatment according to the protocol. The mean radiation 
dose in arms 1–2 was 66.2±7.5 Gy and 67.9±7.4 Gy. 76 patients used 2 
cycle concomitant chemotherapy, 4 cases 3 cycles, and 4 ones 1 cycle 
(3 in arm 1 and 1 in arm 2). Median OS were 23 and 25 months for 
arms 1 and 2, respectively (p=0.224). Concerning toxicities of grade 2 
or more in the arms 1 and 2, the white blood cell was 32/41 and 
20/43 (p=0.003), esophagitis 14/41 and 10/43 (p=0.269), pneumonitis 
8/41 and 6/43 (p=0.494), vomiting 13/41 and 9/43 (p=0.261), 
hemotoblatin 8/41 and 5/43 (p=0.318), platelet 9/41 and 5/43 
(p=0.204), respectively. 
Conclusions: Concurrent cisplatin with pemtrexed and LCAHRT was as 
effective as with vinorelbine for unresectable stage III non–small cell 
lung cancer, however, the treatment compatibility was better.  
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